The results showed that ANXA5, STAT1, CD44, CAV1, and ANXA2 not only were upregulated in GBM and LGG tissue samples (Figure 3E) but also were significantly associated with worse prognosis in LGG patients, particularly the ANXA5, while no significant difference was found in GBM patients (Figures 4A, B). This evidence concerns the gene ANXA2 and glioblastoma.